When the market gets a little sketchy, investors might tend to prefer the “blue chip” companies vs. the smaller companies due to the perceived safety in the bigger names.To isolate those bigger names, the most common method is by searching for companies with the largest market capitalization.Market cap is defined as the total dollar market value of all of a […]
Source: Celgene CorporationIt’s been proven time and time again that investing for the long haul outperforms short-term trading, but biotechnology stock investors must also realize that the industry moves so quickly that only the best-of-breed players ought to be stashed away for the long term. For that reason, while I’m happy to own a few speculative biotech stocks here and […]
Biotech companies are restoring sight to the blind, curing hepatitis C and fighting off HIV.As they save lives, biotech companies are simultaneously making a lot of money for investors.That’s why the hottest ETFs (exchange-traded funds) on the planet since the bull market began in March 2009 invest in biotech companies.The First Trust NYSE Arca Biotech ETF (FBT) has skyrocketed more […]
Update 1/27 After the Close Amgen Beats
Amgen, Inc (AMGN) fourth quarter earnings and sales beat estimates on strong sales of Enbrel, an arthritis drug.Revenue for Q4 was $5,33B a 6% increase over Q4 2013, The stock was up slightly after hours to $159.40. Sales growth was also driven by Kyprolis and Prolia. The P/S is still a modest 6.12 and […]
Biotech is big, and the industry has been big for quite some time.As a matter of fact, biotechnology has been the second-best performing industry over the last two years.Biotech stocks obviously come in all different shapes and sizes. Some investors like the small-caps, others prefer the middle of the road mid-caps.However, at the end of the day, the big biotechs […]
The biotech sector has started 2015 with the announcement of several deals. Both Kite Pharma (KITE – Snapshot Report) and Isis Pharmaceuticals (ISIS – Analyst Report) saw their share prices increasing on collaboration agreements with major companies. Meanwhile, Alkermes (ALKS – Analyst Report) has also started the year on a positive note with encouraging pipeline data.Recap of the Week’s Most […]
By Ben LevisohnRBC’s Michael Yee and team explain why Celgene (CELG), Biogen Idec (BIIB), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN) and Regeneron Pharmaceuticals (REGN) are their top biotech stocks for 2015:
Bloomberg News
Top-five longs: Celgene, Biogen Idec, BioMarin Pharmaceutical, Vertex Pharmaceuticals, Regeneron Pharmaceuticals: 1) Celgene we predict “settlement” with Actavis (ACT) could happen after spring when expert discovery ends and before Court begins mid-15; plus investors should start giving […]
Mergers and acquisitions show no signs of slowing down in the biotech sector with a $3.5 billion acquisition agreement being announced. Meanwhile, Biogen (BIIB – Analyst Report) is advancing towards developing a treatment for Alzheimer’s disease.Recap of the Week’s Most Important Stories1. Biogen is set to move its experimental Alzheimer’s disease treatment, BIIB037, into late-stage testing based on promising interim […]
While biotech stocks saw an early selloff Friday, the shares of three companies in the sector have plenty of potential left, John Schroer of Allianz Global Investors said on CNBC.Biogen Idec is his top pick.”Leading company in the [multiple sclerosis] space. They have some very strong earnings growth, 20 to 25 percent earnings growth over the next three years. And […]
moreView todays social media effects on BIIBView the latest stocks trending across Twitter. Click to view dashboardSee who Biogen is hiring next, click here to view […]
